Importantly, the use of two different CXCR4 antagonists confirmed that SDF‐1 signalling is involved in the therapeutic effects of LAV‐BPIFB4, including prevention of contractile dysfunction, possibly through induction of MyHC‐α and a reduction in myocardial fibrosis, microangiopathy, and endothelial dysfunction. Here, BPIFB4 is linked to endothelial dysfunction.